Hyderabad, May 27 (UNI) Suven Life Sciences Limited today announced that product patents were granted in Russia and Australia for two of their New Chemical Entities (NCEs) for treatment of disorders associated with neuro-degenerative diseases.
According to a press release here, the granted claims of the patents valid till 2023, include the class of selective 5-HT compounds discovered by Suven.
These granted patents were exclusively intellectual property of Suven achieved through the internal discovery research efforts.
Products out of these inventories, which were in pre-clinical development, might be out-licensed at the stage of clinical phase one or phase two, the release added.
UNI AP VA ROY 1429